Page 17 - 2021_03-Haematologica-web

Editorials
venous iron,9 reluctance to its use among practitioners prevails due to heightened concerns of danger fomented, at least in part, by misinformation and misinterpretation of the incidence and clinical nature of serious adverse events occurring in recipients of this treatment.10 The con- vincing evidence brought forth from these well-per- formed in vitro experiments and animal models provides information not only on a long-sought physiological mechanism for a commonly observed clinical event but more importantly on the need to heighten the awareness of a readily prescribed treatment modality which miti- gates its occurrence.
Disclosures
HA-S: no conflicts of interest relevant to the present manu- script; consultancy (for Agios, Dova, Rigel and Argenx) and research funding (from Agios, Dova and Amgen). CMK: no relevant financial disclosures; MA: research funding from AMAG Pharma (manufacturer of the IV iron ferumoxytol) and have done educational non-promotional talks for Pfizer and Pharmacosmos.
Contributions
Each of the authors contributed to the concept of the editorial, drafting the manuscript, critically revising it and designing the figure. All authors approved the final version.
Acknowledgments
HA-S is the recipient of the Harvard KL2/Catalyst Medical Research Investigator Training Award and an American Society of Hematology Scholar Award.
References
1. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood. 1999;93(10):3286-3293.
2.Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol. 2012;87(3):308-310.
3. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epo- etin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-242.
4. Song AB, Kuter DJ, Al-Samkari H. Characterization of the rate, predic- tors, and thrombotic complications of thrombocytosis in iron deficien- cy anemia. Am J Hematol. 2020 Jul 3. doi: 10.1002/ajh.25925. [Epub ahead of print].
5. Jimenez K, Leitner F, Leitner A, et al. Iron deficiency-induced throm- bocytosis increases thrombotic tendency in rats. Haematologica. 2020;106(3):783-795.
6. Gascon P, Nagarkar R, Smakal M, et al. A randomized, double-blind, placebo-controlled, phase III noninferiority study of the long-term safety and efficacy of darbepoetin alfa for chemotherapy-induced anemia in patients with advanced NSCLC. J Thorac Oncol. 2020;15(2):190-202.
7.Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3(7):a011866
8.Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139(2):289-296.
9. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12-23.
10. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369(9572):1502-1504.
haematologica | 2021; 106(3)
663